AT2 Agonist Compounds With Metabolic Stability for ILD Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for interstitial lung diseases (ILDs), particularly idiopathic pulmonary fibrosis (IPF), are limited in efficacy and safety, with existing drugs causing side effects and lacking metabolic stability, and there is a need for more potent and selective angiotensin II type 2 (AT2) receptor agonists that minimize CYP enzyme inhibition.
Innovation Solution
Development of chemically-modified compounds that act as selective AT2 receptor agonists with improved metabolic stability and reduced CYP enzyme inhibition, including specific alkyl, alkoxy, and aryl substitutions, which are formulated as pharmaceutically-acceptable salts, solvates, and stereoisomers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing AT2 receptor agonists are used to treat ILDs, then therapeutic effects are achieved, but metabolic stability is poor and CYP enzyme inhibition occurs causing side effects
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of AT2 receptor agonists through specific substitutions (R1-R6 groups, Y1-Y4 linkers) to alter metabolic stability and reduce CYP enzyme inhibition. The systematic variation of chemical parameters in formula I compounds resolves the contradiction between maintaining therapeutic efficacy and improving metabolic profile.
Solution Approach 2:
The patent applies local quality by introducing specific substituent groups at defined positions (R1-R6) on the core molecular structure. Each substitution locally modifies the compound's interaction with metabolic enzymes and receptors, thereby improving metabolic stability without compromising overall therapeutic effect.
2Reliability
If existing AT2 receptor agonists are used, then some therapeutic benefit is achieved, but potency is insufficient and side effects occur
Solution Approach 1:
The patent systematically varies chemical parameters (alkyl chain lengths, aromatic substitutions, heteroatom positions) to optimize binding affinity and potency at the AT2 receptor. This resolves the contradiction by achieving higher potency through precise structural modification while the improved metabolic stability inherently reduces side effects.
3Productivity
If current ILD treatments are used, then some symptomatic relief is achieved, but efficacy is limited and safety concerns arise
Solution Approach 1:
The patent applies parameter changes to create novel AT2 agonists with optimized pharmacokinetic and pharmacodynamic properties. The modified compounds achieve superior therapeutic efficacy through enhanced receptor selectivity and potency, while improved metabolic stability eliminates safety concerns related to CYP enzyme inhibition and metabolic instability.
Data Source
AI summary
There is provided herein a compound of formula I,wherein R1, R2, R3 Y1, Y2, Y3, Y4, R4, R5 and R6 are as defined herein, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.